ABUS Arbutus Biopharma Corporation - Common Stock
$5,01
Fiyat · Ağu 19, 2026
Temel veriler itibarıyla Ağu 12, 2026
52 Haftlık Aralık
$3–$5
81% of range
Analist Derecelendirmesi
BUY
8 analysts
Fiyat Hedefi
$6
+10% upside
P/E (TTM)
-30.1
ROE
-42.0%
Net Kâr Marjı
-237.9%
Arbutus Biopharma Corporation - Common Stock Hakkında Wikipedia'dan şirket genel bakışı
Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
Devamını oku
Arbutus Biopharma Corporation is a publicly traded Canadian (NASDAQ: ABUS) biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection.
It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007.
History
Tekmira, as the company was formerly called, was formed as a wholly owned subsidiary of Inex Pharmaceuticals in 2005 after that company began collapsing after its regulatory and partnering strategy failed in 2004. Tekmira was fully spun out in 2007 and Tekmira absorbed the assets of Inex, which had been founded in 1992.
Inex had been developing liposomal formulations of off-patent cancer drugs, and licensed them to Talon Pharmaceuticals in 2005; Talon was acquired by Spectrum Pharmaceuticals in 2013, and three former Inex/Tekmira products reached the market and began generating royalties for Tekmira: Marqibo (liposomal vincristine), Alocrest (liposomal vinorelbine) and Brakiva (liposomal topotecan).
Inex had also acquired licenses to intellectual property, as well as staff and manufacturing facilities, concerning RNAi technology from Lynx Therapeutics in 1998; this set of technologies became the focus for Tekmira and it initially sought to develop liposomally encapsulated RNAi drugs for a broad range of indications.
Tekmira also worked on providing liposomal delivery technology to other companies. In 2007 it signed a license agreement with Alnylam Pharmaceuticals so that Alnylam could use it to deliver its own RNAi drugs; that deal was expanded into a manufacturing agreement in 2009.
Most of those products not focused on viral diseases faltered, and Tekmira had only $6.3 million in cash when it filed suit against Alnylam in 2011 for breaching its contract and stealing trade secrets. The suit was settled in 2012, with Alnylam agreeing to pay Tekmira $65 million in termination fees, and the companies negotiated a new license agreement with lower milestones and royalties, which covers Alnylam's product patisiran.
Tekmira caught the world's attention and its stock rose dramatically during the 2013 West African Ebola virus epidemic due to its drug candidate for Ebola fever, TKM-Ebola. Tekmira was developing it under a $140 million US Department of Defense contract. While its stock was trading high in January 2015, it acquired OnCore BioPharma, a company focused on hepatitis B.
On December 19, 2014, Tekmira announced the appointment of former Bill & Melinda Gates Foundation CFO Richard Henriques to the company's board of directors. The company simultaneously announced the forthcoming departure of Ian MacLachlan as Executive Vice President and Chief Technical Officer.
Development of TKM-Ebola was terminated in mid June 2015 during a Phase II trial, for lack of efficacy.
The next month, Tekmira changed its name to Arbutus Biopharma and said that it would focus on drugs to treat hepatitis B.
In March 2017 Arbutus signed another license for its liposome delivery technology, this time with Alexion Pharmaceuticals, for delivery of an mRNA drug candidate. This license was terminated in July 2017, when Alexion discontinued preclinical programs outside its core complement franchise.
In 2019, Arbutus began a phase 1 clinical study using AB-506 to treat chronic hepatitis B. The company released preliminary data in July and stopped the trial in October after two patients developed acute hepatitis. Now AB-729 is paving the way for Arbutus, as they recently received the FDA go ahead to pursue phase 2 trials, after having their data voted best in ILC, 2021; after abandoning development of previous investigational agents. AB-836, Arbutus's next generation capsid inhibitor, has shown potential against mutants in its phase 1 trials.
In July 2019, Arbutus Biopharma announced the sale of part of its royalty interest on future global net sales of ONPATTRO, an RNA interference therapeutic currently sold by Alnylam Pharmaceuticals, to OMERS for $20 million.
COVID-19
On March 10, 2023, U.S. District Judge Mitchell Goldberg rejected a bid by Moderna to dismiss some of the patent infringement claims brought against the company by Arbutus and its partner, Genevant Sciences.
Moderna settled their lawsuit and will pay Arbutus $950 million upfront and an additional $1.3 billion contingent upon a favorable resolution of Moderna’s Section 1498 appeal.
Kaynak: Wikipedia (İngilizce), CC BY-SA 4.0 · Wikipedia'da Görüntüle ↗
ABUS Hisse Senedi Özeti Fiyat, piyasa değeri, P/E, EPS, ROE, borç/öz sermaye, 52 haftalık aralık
Fiyat
$5.01
Piyasa Değeri
$987M
P/E (TTM)
-30.1
EPS (TTM)
$-0.17
Gelir (TTM)
$14M
Temettü Verimi
—
ROE
-42.0%
D/E Borç/Özsermaye
—
52 Haftlık Aralık
$3 – $5
ABUS Hisse Senedi Fiyat Grafiği Teknik göstergeler ile günlük OHLCV — kaydır, yakınlaştır ve görünümünüzü özelleştirin
Configure
10 Yıllık Performans Gelir, net kar, marjlar ve EPS trendleri
Gelir ve Net Gelir
$14M
2016-12-31
→
2025-12-31
Hisse Başına Kâr
$-0.17
2016-12-31
→
2025-12-31
Serbest Nakit Akışı
$-40M
2016-12-31
→
2025-12-31
Marjlar
-237.9%
Değerleme P/E, P/S, P/B, EV/EBITDA oranları — hisse senedi pahalı mı ucuz mu?
Metrik
5 Yıllık trend
ABUS
Akran Ortalaması
P/E (TTM)
-30.1
6.7
P/S (TTM) (F/S (TTM))
70.1
39.8
P/B (F/D)
12.9
4.8
Price / FCF (Fiyat / Serbest Nakit Akışı)
-24.9
—
Kârlılık Brüt, faaliyet ve net kâr marjları; ROE, ROA, ROIC
Metrik
5 Yıllık trend
ABUS
Akran Ortalaması
Operating Margin (Faaliyet Kâr Marjı)
-271.0%
—
Net Profit Margin (Net Kâr Marjı)
-237.9%
-220.1%
ROA
-29.6%
-35.0%
ROE
-42.0%
-43.2%
Finansal Sağlık Borç, likidite, solventlik — bilanço gücü
Metrik
5 Yıllık trend
ABUS
Akran Ortalaması
Current Ratio (Cari Oran)
15.7
9.7
Quick Ratio (Cari Oran)
15.5
—
Büyüme Gelir, EPS ve net gelir büyümesi: YOY, 3 Yıllık CAGR, 5 Yıllık CAGR
Metrik
5 Yıllık trend
ABUS
Akran Ortalaması
Revenue YoY (Gelir Yıllık Bazda)
128.2%
—
Revenue CAGR 3Y (Gelir 3 Yıllık Bileşik Büyüme Oranı)
-28.8%
—
Revenue CAGR 5Y (Gelir 5 Yıllık Bileşik Büyüme Oranı)
15.3%
—
Sermaye Verimliliği Aktif devir hızı, stok devir hızı, alacak devir hızı
Metrik
5 Yıllık trend
ABUS
Akran Ortalaması
ABUS Analist Uzlaşması Boğa ve ayı analist görüşleri, 12 aylık fiyat hedefi, yukarı yönlü potansiyel
AL
8 analist
- Güçlü Al 3 37,5%
- Al 4 50,0%
- Tut 1 12,5%
- Sat 0 0,0%
- Güçlü Sat 0 0,0%
12 Aylık Fiyat Hedefi
1 analist · 2026-08-17
Düşük
$5.53
Yüksek
$5.53
Medyan hedef
$5.53
+10,3%
Ortalama hedef
$5.53
+10,3%
Kazanç Geçmişi EPS gerçekleşen vs tahmin, sürpriz %, kazanma oranı, bir sonraki kazanç tarihi
Ort. Sürpriz
0.01%
| Dönem | EPS Gerçek | EPS Tahmin | Sürpriz |
|---|---|---|---|
| 31 Mart 2026 | $-0.05 | $-0.03 | -0.02% |
| 31 Aralık 2025 | $-0.02 | $-0.04 | 0.02% |
| 30 Eylül 2025 | $-0.04 | $-0.03 | -0.01% |
| 30 Haziran 2025 | $0.01 | $-0.05 | 0.06% |
| 31 Mart 2025 | $-0.13 | $-0.11 | -0.02% |
| 31 Aralık 2024 | $-0.07 | $-0.08 | 0.01% |
Akran karşılaştırması (GICS alt sektörü) Anahtar metrikler sektördeki benzerlerine karşı
| Hisse Sembolü | Piyasa Değeri | P/E | Gelir YoY | Net Kar Marjı | ROE | Brüt Kar Marjı |
|---|---|---|---|---|---|---|
| ABUS | $926M | -28.3 | 128.2% | -237.9% | -42.0% | — |
| XENE | $3.59B | -10.3 | — | -4612.1% | -56.9% | — |
| AUPH | $2.11B | 7.7 | 20.4% | 101.5% | 62.7% | — |
| ZYME | $1.97B | -24.4 | 38.9% | -76.6% | -26.9% | — |
| ACOG | $141M | -5.5 | — | -202.2% | -43.8% | — |
Tüm Temeller Tüm metrikler yıla göre — gelir tablosu, bilanço, nakit akışı
Gelir Tablosu 16
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14M | $6M | $18M | $39M | $11M | $7M | $6M | $6M | $11M | $1M | $23M | |
| R&D Expense | $25M | $54M | $74M | $84M | $66M | $49M | $58M | $58M | $63M | $61M | $52M | |
| SG&A Expense | $16M | $22M | $22M | $18M | $17M | $15M | $18M | $16M | $16M | $39M | $26M | |
| Operating Expenses | $52M | $82M | $96M | $104M | $85M | $65M | $150M | $96M | $122M | $493M | $127M | |
| Operating Income | $-38M | $-76M | $-78M | $-65M | $-74M | $-58M | $-144M | $-90M | $-111M | $-492M | $-104M | |
| Interest Expense | · | · | $459.0K | $2M | $3M | $4M | $2M | $226.0K | $261.0K | $0 | $0 | |
| Interest Income | $4M | $7M | $6M | $2M | $127.0K | $741.0K | $2M | $3M | $2M | $1M | $674.0K | |
| Other Non-op | $5M | $6M | $5M | $444.0K | $-3M | $-6M | $-22M | $28M | $2M | $2M | $25M | |
| Pretax Income | · | · | · | · | · | $-64M | $-166M | $-61M | $-109M | $-489M | $-79M | |
| Income Tax | $0 | $0 | $0 | $4M | $0 | $0 | $-13M | $-4M | $-24M | $-105M | $-16M | |
| Net Income | $-34M | $-70M | $-73M | $-69M | $-76M | $-64M | $-154M | $-57M | $-84M | $-384M | $-63M | |
| EPS (Basic) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 | · | $-1.21 | $-1.56 | $-7.24 | $-1.38 | |
| EPS (Diluted) | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 | $-1.00 | · | $-1.21 | $-1.56 | $-7.24 | $-1.38 | |
| Shares (Basic) | 191,599,600 | 185,608,874 | 165,960,379 | 150,939,337 | 106,242,452 | 75,835,378 | · | 55,304,083 | 54,723,272 | 53,074,401 | 45,462,324 | |
| Shares (Diluted) | 191,599,600 | 185,608,874 | 165,960,379 | 150,939,337 | 106,242,452 | 75,835,378 | · | 55,304,083 | 54,723,272 | 53,074,401 | 45,462,324 | |
| EBITDA | $-38M | $-76M | $-78M | $-65M | $-74M | $-58M | · | $-90M | $-111M | $-492M | · |
Bilanço 25
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $18M | $36M | $26M | $31M | $109M | $52M | $32M | $37M | $54M | $23M | $167M | |
| Short-term Investments | $73M | $86M | $100M | $116M | $46M | $71M | $59M | $88M | $72M | $107M | $15M | |
| Receivables | $1M | $2M | $2M | $1M | $899.0K | $1M | $1M | $1M | $402.0K | $273.0K | $1M | |
| Prepaid Expense | $2M | $2M | $4M | $3M | $4M | $3M | $2M | $3M | $2M | $1M | $1M | |
| Current Assets | $94M | $127M | $132M | $151M | $161M | $128M | $94M | $129M | $129M | $133M | $184M | |
| PP&E (Net) | $32.0K | $3M | $5M | $5M | $6M | $7M | $9M | $10M | $12M | $7M | $3M | |
| PP&E (Gross) | $245.0K | $16M | $17M | $16M | $15M | $15M | $14M | $17M | $25M | $18M | $13M | |
| Accum. Depreciation | $213.0K | $13M | $12M | $11M | $9M | $8M | $6M | $7M | $13M | $11M | $10M | |
| Goodwill | · | · | · | · | · | · | $0 | $22M | $24M | $24M | $163M | |
| Intangibles | · | · | · | · | · | · | $0 | $44M | $59M | $99M | $353M | |
| Other Non-current Assets | $130.0K | $34.0K | $0 | $103.0K | $61.0K | $44.0K | $293.0K | $0 | · | · | · | |
| Total Assets | $95M | $132M | $144M | $195M | $204M | $137M | $106M | $228M | $237M | $276M | $712M | |
| Accounts Payable | $5M | $8M | $10M | $16M | $11M | $9M | $7M | $9M | $11M | $10M | $9M | |
| Current Liabilities | $6M | $16M | $22M | $33M | $11M | $10M | $8M | $11M | $15M | $11M | $11M | |
| Capital Leases | $199.0K | $806.0K | $1M | $2M | $2M | $3M | $3M | $0 | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $0 | $13M | $17M | $41M | $146M | |
| Total Liabilities | $18M | $34M | $38M | $59M | $35M | $35M | $33M | $28M | $55M | $73M | $165M | |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | · | · | · | · | · | · | |
| Common Stock | $1.42B | $1.41B | $1.35B | $1.32B | $1.29B | $986M | $899M | $879M | $876M | $867M | $834M | |
| Paid-in Capital | $83M | $82M | $81M | $72M | $65M | $61M | $55M | $48M | $43M | $37M | $30M | |
| Retained Earnings | $-1.38B | $-1.35B | $-1.28B | $-1.20B | $-1.13B | $-1.05B | $-970M | $-805M | $-738M | $-653M | $-267M | |
| AOCI | $-48M | $-48M | $-48M | $-50M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-50M | |
| Stockholders' Equity | $77M | $97M | $106M | $137M | $169M | $102M | $73M | $200M | $182M | $203M | $548M | |
| Liabilities + Equity | $95M | $132M | $144M | $195M | $204M | $137M | $106M | $228M | $237M | $276M | $712M | |
| Shares Outstanding | 192,531,225 | 189,963,492 | 169,867,414 | 157,455,363 | 144,987,736 | 89,678,722 | 64,780,314 | 55,518,800 | 55,060,650 | 54,841,494 | 54,570,691 |
Nakit Akışı 14
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $7M | $9M | $9M | $7M | $6M | $6M | $7M | $6M | $15M | · | · | |
| Deferred Tax | · | · | · | · | · | $0 | $-13M | $-4M | $-24M | $-105M | $-16M | |
| Restructuring | $13M | $4M | $0 | · | $0 | $64.0K | $156.0K | $5M | $0 | · | · | |
| Operating Cash Flow | $-40M | $-65M | $-86M | $-35M | $-68M | $-51M | $-71M | $-68M | $-49M | $-58M | $-56M | |
| CapEx | $0 | $182.0K | $1M | $512.0K | $809.0K | $229.0K | $589.0K | $1M | $7M | $4M | $2M | |
| Investing Cash Flow | $16M | $23M | $51M | $-75M | $-13M | $-15M | $28M | $-4M | $28M | $-99M | $8M | |
| Debt Issued | · | · | · | · | · | · | · | · | $0 | $12M | $0 | |
| Net Debt Issued | · | · | · | · | · | · | · | · | $0 | $12M | · | |
| Stock Issued | · | · | · | · | $135M | $86M | $19M | $0 | $0 | $0 | $142M | |
| Net Stock Activity | · | · | · | · | $135M | $86M | · | · | $0 | $0 | · | |
| Financing Cash Flow | $6M | $52M | $31M | $32M | $137M | $87M | $37M | $56M | $49M | $13M | $144M | |
| Net Change in Cash | $-18M | $10M | $-4M | $-79M | $57M | $20M | $-5M | $-17M | $31M | $-143M | $95M | |
| Free Cash Flow | $-40M | $-65M | $-87M | $-36M | $-68M | $-52M | · | $-69M | $-56M | $-62M | · | |
| Levered FCF | · | · | · | · | · | $-56M | · | $-69M | $-56M | · | · |
Kârlılık 7
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% | -836.1% | · | -1510.2% | -1036.7% | -32973.8% | · | |
| Net Margin | -237.9% | -1133.0% | -401.6% | -178.0% | -693.9% | -922.0% | · | -959.8% | -788.9% | -25765.5% | · | |
| Pretax Margin | · | · | · | · | · | -922.0% | · | -1031.8% | -1016.2% | -32807.9% | · | |
| EBITDA Margin | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% | -836.1% | · | -1510.2% | -1036.7% | -32973.8% | · | |
| ROA | -29.6% | -50.6% | -42.9% | -34.7% | -44.6% | -52.5% | · | -24.5% | -32.9% | -77.8% | · | |
| ROE | -42.0% | -68.5% | -64.6% | -49.2% | -50.9% | -64.0% | · | -27.5% | -43.8% | -102.4% | · | |
| ROIC | · | · | · | · | · | -56.7% | · | -41.7% | -47.2% | -190.2% | · |
Likidite ve Solventlik 3
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 15.7 | 8.2 | 5.9 | 4.6 | 14.3 | 13.4 | · | 11.5 | 8.8 | 12.5 | · | |
| Quick Ratio | 15.5 | 8.0 | 5.7 | 4.5 | 13.9 | 13.1 | · | 11.2 | 8.7 | 12.4 | · | |
| Interest Coverage | · | · | -170.2 | -37.9 | -25.7 | -14.4 | · | -397.3 | -425.0 | · | · |
Verimlilik 2
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.0 | 0.1 | 0.2 | 0.1 | 0.1 | · | 0.0 | 0.0 | 0.0 | · | |
| Receivables Turnover | 7.3 | 2.9 | 11.6 | 34.7 | 9.9 | 5.5 | · | 6.5 | 31.7 | 2.3 | · |
Büyüme Oranları 3
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 128.2% | -66.0% | -53.5% | 255.1% | 58.9% | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -28.8% | -17.5% | 37.9% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 15.3% | · | · | · | · | · | · | · | · | · | · |
Değerleme (TTM) 10
| Metrik | Eğilim | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $14M | $6M | $18M | $39M | $11M | $7M | $6M | $6M | $11M | $1M | $23M | |
| Net Income TTM | $-34M | $-70M | $-73M | $-69M | $-76M | $-64M | $-154M | $-57M | $-84M | $-384M | $-63M | |
| Market Cap | $926M | $621M | $425M | $367M | $564M | $318M | · | $213M | $278M | $134M | · | |
| P/E | -28.3 | -8.6 | -5.7 | -5.1 | -4.7 | -3.5 | -2.1 | -3.2 | -3.2 | -0.3 | -3.2 | |
| P/S | 65.8 | 100.7 | 23.4 | 9.4 | 51.3 | 46.0 | · | 35.8 | 26.0 | 90.1 | · | |
| P/B | 12.1 | 6.4 | 4.0 | 2.7 | 3.3 | 3.1 | · | 1.1 | 1.5 | 0.7 | · | |
| P / Tangible Book | 12.1 | 6.4 | 4.0 | 2.7 | 3.3 | 3.1 | · | · | · | · | · | |
| P / Cash Flow | -23.4 | -9.6 | -4.9 | -10.4 | -8.4 | -6.2 | · | -3.1 | -5.7 | -2.3 | · | |
| P / FCF | -23.4 | -9.6 | -4.9 | -10.2 | -8.3 | -6.2 | · | -3.1 | -5.0 | -2.2 | · | |
| Earnings Yield | -3.5% | -11.6% | -17.6% | -19.7% | -21.3% | -28.2% | -47.5% | -31.6% | -30.9% | -295.5% | -31.0% |
Gelir Tablosu 16
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1M | $179M | $1M | $529.0K | $11M | $2M | $2M | $1M | $2M | $2M | $2M | $5M | $5M | $7M | $6M | $6M | |
| R&D Expense | $3M | $4M | $5M | $6M | $5M | $9M | $9M | $14M | $16M | $15M | $18M | $20M | $18M | $18M | $23M | $20M | |
| SG&A Expense | $4M | $6M | $4M | $3M | $3M | $6M | $5M | $5M | $8M | $5M | $5M | $6M | $6M | $6M | $4M | $3M | |
| Operating Expenses | $7M | $10M | $6M | $9M | $9M | $27M | $16M | $23M | $23M | $21M | $23M | $26M | $23M | $24M | $29M | $24M | |
| Operating Income | $-6M | $169M | $-5M | $-9M | $1M | $-26M | $-14M | $-21M | $-22M | $-19M | $-21M | $-22M | $-18M | $-17M | $-23M | $-18M | |
| Interest Expense | · | · | · | · | · | · | · | · | $34.0K | $44.0K | · | $46.0K | $171.0K | $198.0K | $309.0K | $429.0K | |
| Interest Income | $842.0K | $815.0K | $877.0K | $952.0K | $1M | $1M | $1M | $2M | $2M | $2M | $1M | $1M | $1M | $1M | $943.0K | $694.0K | |
| Other Non-op | $821.0K | $787.0K | $2M | $917.0K | $1M | $1M | $1M | $2M | $2M | $1M | $1M | $1M | $1M | $1M | $630.0K | $244.0K | |
| Pretax Income | · | · | · | · | · | · | · | · | · | · | · | $-20M | $-17M | $-16M | · | $-18M | |
| Income Tax | $0 | $0 | · | · | · | · | · | · | · | · | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $-5M | $170M | $-4M | $-8M | $3M | $-25M | $-13M | $-20M | $-20M | $-18M | $-19M | $-20M | $-17M | $-16M | $-22M | $-18M | |
| EPS (Basic) | $-0.03 | $0.88 | $-0.01 | $-0.04 | $0.01 | $-0.13 | $-0.07 | $-0.10 | $-0.11 | $-0.10 | $-0.12 | $-0.12 | $-0.10 | $-0.10 | $-0.13 | $-0.12 | |
| EPS (Diluted) | $-0.03 | $0.87 | $-0.01 | $-0.04 | $0.01 | $-0.13 | $-0.07 | $-0.10 | $-0.11 | $-0.10 | $-0.12 | $-0.12 | $-0.10 | $-0.10 | $-0.13 | $-0.12 | |
| Shares (Basic) | 197,470,724 | 193,768,641 | -382,437,717 | 191,778,950 | 191,551,282 | 190,707,085 | -367,055,361 | 188,997,194 | 188,041,489 | 175,625,552 | -329,259,017 | 167,512,708 | 166,063,284 | 161,643,404 | -297,234,228 | 150,995,191 | |
| Shares (Diluted) | 197,470,724 | 195,214,067 | -383,286,168 | 191,778,950 | 192,399,733 | 190,707,085 | -367,055,361 | 188,997,194 | 188,041,489 | 175,625,552 | -329,259,017 | 167,512,708 | 166,063,284 | 161,643,404 | -297,234,228 | 150,995,191 | |
| EBITDA | $-6M | $169M | · | $-9M | $1M | $-25M | · | $-21M | $-22M | $-19M | · | $-22M | $-18M | $-17M | · | $-18M |
Bilanço 22
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $19M | $24M | $18M | $22M | $37M | $37M | $36M | $32M | $63M | $43M | $26M | $18M | $27M | $41M | $31M | $24M | |
| Short-term Investments | · | · | $73M | · | · | · | $86M | · | · | · | $100M | · | · | · | $116M | · | |
| Receivables | $369.0K | $1M | $1M | $905.0K | $1M | $1M | $2M | $2M | $2M | $2M | $2M | $2M | $3M | $3M | $1M | $2M | |
| Prepaid Expense | $2M | $2M | $2M | $3M | $4M | $3M | $2M | $3M | $4M | $4M | $4M | $5M | $4M | $3M | $3M | $5M | |
| Current Assets | $274M | $277M | $94M | $97M | $103M | $117M | $127M | $133M | $148M | $136M | $132M | $142M | $159M | $153M | $151M | $141M | |
| PP&E (Net) | $10.0K | $22.0K | $32.0K | $137.0K | $148.0K | $168.0K | $3M | $4M | $4M | $4M | $5M | $5M | $5M | $5M | $5M | $5M | |
| PP&E (Gross) | · | · | $245.0K | · | · | · | $16M | · | · | · | $17M | · | · | · | $16M | · | |
| Accum. Depreciation | $235.0K | $224.0K | $213.0K | $13M | $13M | $13M | $13M | $13M | $13M | $12M | $12M | $12M | $11M | $11M | $11M | $10M | |
| Other Non-current Assets | $132.0K | $131.0K | $130.0K | $131.0K | $0 | $34.0K | $34.0K | · | · | · | $0 | $3.0K | $11.0K | $62.0K | $103.0K | $167.0K | |
| Total Assets | $274M | $277M | $95M | $98M | $103M | $117M | $132M | $140M | $160M | $150M | $144M | $159M | $177M | $191M | $195M | $204M | |
| Accounts Payable | $3M | $4M | $5M | $5M | $5M | $12M | $8M | $8M | $11M | $8M | $10M | $10M | $9M | $10M | $16M | $12M | |
| Current Liabilities | $3M | $5M | $6M | $5M | $5M | $19M | $16M | $19M | $23M | $20M | $22M | $22M | $25M | $25M | $33M | $28M | |
| Capital Leases | $0 | $0 | $199.0K | $391.0K | $575.0K | $626.0K | $806.0K | $978.0K | $1M | $1M | $1M | $1M | $2M | $2M | $2M | $2M | |
| Total Liabilities | $15M | $17M | $18M | $20M | $20M | $38M | $34M | $34M | $38M | $36M | $38M | $39M | $42M | $47M | $59M | $58M | |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | $0 | $0 | · | $0 | |
| Common Stock | $1.45B | $1.44B | $1.42B | $1.42B | $1.42B | $1.42B | $1.41B | $1.41B | $1.40B | $1.38B | $1.35B | $1.35B | $1.34B | $1.34B | $1.32B | $1.31B | |
| Paid-in Capital | $74M | $74M | $83M | $83M | $83M | $82M | $82M | $81M | $82M | $80M | $81M | $80M | $77M | $74M | $72M | $71M | |
| Retained Earnings | $-1.22B | $-1.21B | $-1.38B | $-1.38B | $-1.37B | $-1.37B | $-1.35B | $-1.33B | $-1.31B | $-1.29B | $-1.28B | $-1.26B | $-1.24B | $-1.22B | $-1.20B | $-1.18B | |
| AOCI | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-48M | $-49M | $-49M | $-50M | $-50M | $-51M | |
| Stockholders' Equity | $259M | $260M | $77M | $77M | $83M | $79M | $97M | $107M | $122M | $115M | $106M | $119M | $135M | $144M | $137M | $146M | |
| Liabilities + Equity | $274M | $277M | $95M | $98M | $103M | $117M | $132M | $140M | $160M | $150M | $144M | $159M | $177M | $191M | $195M | $204M | |
| Shares Outstanding | 197,634,118 | 196,947,757 | 192,531,225 | 191,953,665 | 191,641,511 | 191,481,474 | 189,963,492 | 189,438,135 | 188,739,044 | 180,192,227 | 169,867,414 | 167,695,247 | 166,922,739 | 165,132,193 | 157,455,363 | 152,711,702 |
Nakit Akışı 11
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $11.0K | $11.0K | · | $11.0K | $11.0K | $330.0K | · | $336.0K | $356.0K | $355.0K | · | $369.0K | $342.0K | $334.0K | · | $343.0K | |
| Stock-based Comp | $2M | $1M | $1M | $1M | $864.0K | $4M | $2M | $2M | $3M | $2M | $2M | $2M | $3M | $2M | $2M | $2M | |
| Restructuring | $0 | $0 | $-12M | $98.0K | $165.0K | $12M | $95.0K | $4M | $0 | $0 | $0 | $0 | · | · | · | · | |
| Other Non-cash | · | $-179M | · | · | · | $7M | · | · | · | $-4M | · | · | · | $-13M | · | · | |
| Operating Cash Flow | $-6M | $-8M | $-5M | $-6M | $-16M | $-13M | $-10M | $-21M | $-15M | $-19M | $-17M | $-22M | $-20M | $-27M | $-17M | $-19M | |
| CapEx | · | · | $0 | $0 | $0 | $0 | $86.0K | $0 | $1.0K | $95.0K | $0 | $32.0K | $859.0K | $117.0K | $134.0K | $91.0K | |
| Investing Cash Flow | $-2M | $2M | $-1M | $-10M | $16M | $11M | $13M | $-12M | $10M | $12M | $22M | $10M | $1M | $17M | $13M | $-14M | |
| Financing Cash Flow | $3M | $12M | $2M | $844.0K | $453.0K | $3M | $1M | $2M | $24M | $24M | $4M | $2M | $5M | $20M | $11M | $9M | |
| Net Change in Cash | $-5M | $6M | $-4M | $-15M | $336.0K | $746.0K | $4M | $-31M | $20M | $17M | $9M | $-10M | $-13M | $10M | $7M | $-23M | |
| Free Cash Flow | · | · | · | · | · | $-13M | · | · | · | $-19M | · | · | · | $-27M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | · | · | · | · | $-28M | · | · |
Kârlılık 7
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -588.2% | 94.3% | · | -1636.9% | 13.9% | -1456.9% | · | -1601.2% | -1250.5% | -1263.9% | · | -462.8% | -395.3% | -260.4% | · | -299.2% | |
| Net Margin | -507.2% | 94.7% | · | -1463.5% | 23.5% | -1390.4% | · | -1472.5% | -1146.9% | -1166.8% | · | -431.6% | -367.5% | -244.3% | · | -295.1% | |
| Pretax Margin | · | · | · | · | · | · | · | · | · | · | · | -431.6% | -367.5% | -244.3% | · | -295.1% | |
| EBITDA Margin | -588.2% | 94.3% | · | -1636.9% | 13.9% | -1438.2% | · | -1601.2% | -1250.5% | -1240.7% | · | -462.8% | -395.3% | -255.4% | · | -299.2% | |
| ROA | -2.7% | 86.1% | · | -6.5% | 1.9% | -18.4% | · | -13.2% | -11.8% | -10.5% | · | -11.1% | -8.7% | -7.6% | · | -9.5% | |
| ROE | -3.0% | 100.0% | · | -8.4% | 2.5% | -25.3% | · | -17.4% | -15.4% | -13.8% | · | -15.2% | -11.9% | -10.5% | · | -12.8% | |
| ROIC | · | · | · | · | · | · | · | · | · | · | · | -18.1% | -13.7% | -12.1% | · | -12.2% |
Likidite ve Solventlik 3
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 81.4 | 54.3 | · | 18.8 | 20.5 | 6.0 | · | 7.0 | 6.6 | 6.7 | · | 6.3 | 6.5 | 6.1 | · | 5.1 | |
| Quick Ratio | 5.8 | 4.9 | · | 4.5 | 7.7 | 2.0 | · | 1.8 | 2.9 | 2.2 | · | 0.9 | 1.2 | 1.7 | · | 0.9 | |
| Interest Coverage | · | · | · | · | · | · | · | · | -634.8 | -440.1 | · | -468.7 | -107.5 | -87.9 | · | -41.5 |
Verimlilik 2
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.9 | · | 0.0 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | |
| Receivables Turnover | 1.5 | 143.6 | · | 0.4 | 7.7 | 1.1 | · | 0.7 | 0.8 | 0.6 | · | 2.3 | 2.0 | 3.4 | · | 3.4 |
Değerleme (TTM) 10
| Metrik | Eğilim | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $191M | $192M | · | $14M | $16M | $6M | · | $9M | $13M | $18M | · | $22M | $32M | $39M | · | $36M | |
| Net Income TTM | $159M | $140M | · | $-49M | $-62M | $-82M | · | $-77M | $-75M | $-71M | · | $-71M | $-65M | $-64M | · | $-67M | |
| Market Cap | $949M | $886M | · | $871M | $592M | $668M | · | $729M | $583M | $465M | · | $340M | $384M | $500M | · | $292M | |
| P/E | 5.9 | 6.3 | · | -17.5 | -9.4 | -7.9 | · | -9.0 | -7.2 | -6.1 | · | -4.6 | -5.5 | -7.0 | · | -3.4 | |
| P/S | 5.0 | 4.6 | · | 60.6 | 38.0 | 105.1 | · | 78.8 | 46.4 | 26.5 | · | 15.5 | 12.2 | 12.7 | · | 8.1 | |
| P/B | 3.7 | 3.4 | · | 11.3 | 7.1 | 8.4 | · | 6.8 | 4.8 | 4.1 | · | 2.9 | 2.9 | 3.5 | · | 2.0 | |
| P / Tangible Book | 3.7 | 3.4 | · | 11.3 | 7.1 | 8.4 | · | 6.8 | 4.8 | 4.1 | · | 2.9 | 2.9 | 3.5 | · | 2.0 | |
| P / Cash Flow | · | -109.3 | · | · | · | -49.9 | · | · | · | -24.1 | · | · | · | -18.3 | · | · | |
| P / FCF | · | · | · | · | · | -49.9 | · | · | · | -24.0 | · | · | · | -18.2 | · | · | |
| Earnings Yield | 16.9% | 15.8% | · | -5.7% | -10.7% | -12.6% | · | -11.2% | -13.9% | -16.3% | · | -21.7% | -18.3% | -14.2% | · | -29.8% |
Finansal Tablolar Gelir tablosu, bilanço, nakit akışı — yıllık, son 5 yıl
Gelir Tablosu
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Gelir | $14M | $6M | $18M | $39M | $11M |
| Faaliyet Kâr Marjı % | -271.0% | -1236.7% | -430.5% | -167.8% | -669.1% |
| Net Gelir | $-34M | $-70M | $-73M | $-69M | $-76M |
| Seyreltilmiş Hisse Başı Kâr | $-0.17 | $-0.38 | $-0.44 | $-0.46 | $-0.83 |
Bilanço
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Cari Oran | 15.7 | 8.2 | 5.9 | 4.6 | 14.3 |
| Cari Oran | 15.5 | 8.0 | 5.7 | 4.5 | 13.9 |
Nakit Akışı
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Serbest Nakit Akışı | $-40M | $-65M | $-87M | $-36M | $-68M |
Son Haberler Bu şirketten bahseden son manşetler
Metriklerim Kişisel izleme listeniz — Tam Temeller'den seçilen satırlar
📊
Sizin için önemli olan metrikleri seçin — yukarıdaki Tam Temeller'deki herhangi bir satırın yanındaki ➕ düğmesine tıklayın.
Seçiminiz kaydedildi ve tüm hisse senetlerinde sizinle birlikte gelir.
Kurumsal Sahipler (13F) 191 dosya · $496.0M toplam · Tarih itibarıyla 30 Haziran 2026
Çeyreklik SEC Form 13F'lerinde bu hisse senedini tuttuklarını bildiren kurumlar. Yalnızca uzun pozisyonlar; tek bir başvuru sahibi, ayrı opsiyon bacakları için iki kez görünebilir. Büyük dengeleyici alım/satım bacakları genellikle piyasa yapımını veya korunmuş envanteri yansıtır, yönlü bir inancı değil.
Kurumsal faaliyet — Q2 2026 ve önceki çeyrek
| Yeni pozisyonlar | Çıkan pozisyonlar | Artırıldı | Azaldı | Net hisse senedi değişimi |
|---|---|---|---|---|
| 41 (+9 önceki Ç'ye göre) | 23 (-7 önceki Ç'ye göre) | 55 (+10 önceki Ç'ye göre) | 44 (-9 önceki Ç'ye göre) | +5.4M |
Q1 2026 ile karşılaştırıldı. SEC Form 13F başvuruları, çeyrek sonundan itibaren 45 gün içinde ve geç başvuranlar için kısa bir ek süre içinde tamamlanmalıdır — bu pencere içindeki çeyrekler, en son tam olarak raporlanan çifte tercih edilerek atlanır.
| Kurum | Değer | Hisse senetleri | % izlenen 13F'nin | Tür |
|---|---|---|---|---|
| Two Seas Capital LP | $91.658.798 | 19.095.583 | 18,48% | Hisse senetleri |
| Whitefort Capital Management, LP | $75.812.453 | 15.794.261 | 15,28% | Hisse senetleri |
| VANGUARD GROUP INC | $38.412.670 | 7.986.002 | 7,74% | Hisse senetleri |
| STATE STREET CORP | $37.772.059 | 7.869.179 | 7,62% | Hisse senetleri |
| Rubric Capital Management LP | $36.158.098 | 7.532.937 | 7,29% | Hisse senetleri |
| VANGUARD CAPITAL MANAGEMENT LLC | $33.651.259 | 7.010.679 | 6,78% | Hisse senetleri |
| GEODE CAPITAL MANAGEMENT, LLC | $16.983.987 | 3.537.471 | 3,42% | Hisse senetleri |
| BlackBarn Capital Partners LP | $12.000.000 | 2.500.000 | 2,42% | Hisse senetleri |
| Woodline Partners LP | $10.952.909 | 2.281.856 | 2,21% | Hisse senetleri |
| GOLDMAN SACHS GROUP INC | $8.545.829 | 1.780.381 | 1,72% | Hisse senetleri |
| Jefferies Financial Group Inc. | $8.216.026 | 1.711.672 | 1,66% | Hisse senetleri |
| NOMURA HOLDINGS INC | $7.857.989 | 1.637.081 | 1,58% | Hisse senetleri |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $7.398.998 | 1.541.458 | 1,49% | Hisse senetleri |
| BANK OF AMERICA CORP /DE/ | $7.169.851 | 1.493.719 | 1,45% | Hisse senetleri |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $6.869.846 | 1.431.218 | 1,38% | Hisse senetleri |
| OSAIC HOLDINGS, INC. | $6.469.756 | 1.347.866 | 1,30% | Hisse senetleri |
| ADAR1 Capital Management, LLC | $6.087.106 | 1.268.147 | 1,23% | Hisse senetleri |
| Deltroit Asset Management (UK) LLP | $5.760.000 | 1.200.000 | 1,16% | Hisse senetleri |
| VANGUARD FIDUCIARY TRUST CO | $5.449.738 | 1.135.362 | 1,10% | Hisse senetleri |
| CITIGROUP INC | $4.175.784 | 869.955 | 0,84% | Hisse senetleri |
| BANK OF MONTREAL /CAN/ | $3.734.102 | 777.938 | 0,75% | Hisse senetleri |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $3.123.360 | 650.700 | 0,63% | Hisse senetleri |
| MACKENZIE FINANCIAL CORP | $2.946.269 | 613.806 | 0,59% | Hisse senetleri |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $2.889.638 | 602.008 | 0,58% | Hisse senetleri |
| Western Standard LLC | $2.605.378 | 542.787 | 0,53% | Hisse senetleri |
| Rangeley Capital, LLC | $2.400.000 | 500.000 | 0,48% | Hisse senetleri |
| Man Group plc | $2.272.642 | 473.467 | 0,46% | Hisse senetleri |
| Corbin Capital Partners, L.P. | $2.231.732 | 682.487 | 0,45% | Hisse senetleri |
| CenterBook Partners LP | $2.136.725 | 445.151 | 0,43% | Hisse senetleri |
| Freestone Capital Holdings, LLC | $2.124.000 | 442.500 | 0,43% | Hisse senetleri |
| CITADEL ADVISORS LLC | $1.942.541 | 404.696 | 0,39% | Hisse senetleri |
| KENNEDY CAPITAL MANAGEMENT LLC | $1.849.430 | 385.298 | 0,37% | Hisse senetleri |
| Swiss National Bank | $1.375.200 | 286.500 | 0,28% | Hisse senetleri |
| Ledgewood Wealth Advisors, LLC | $1.336.493 | 278.436 | 0,27% | Hisse senetleri |
| FMR LLC | $1.277.232 | 266.090 | 0,26% | Hisse senetleri |
| Susquehanna Portfolio Strategies, LLC | $1.265.688 | 263.685 | 0,26% | Hisse senetleri |
| Carrera Capital Advisors | $1.234.402 | 257.167 | 0,25% | Hisse senetleri |
| Quinn Opportunity Partners LLC | $1.225.027 | 255.214 | 0,25% | Hisse senetleri |
| D. E. Shaw & Co., Inc. | $1.209.614 | 252.003 | 0,24% | Hisse senetleri |
| STATE OF WISCONSIN INVESTMENT BOARD | $1.161.682 | 242.017 | 0,23% | Hisse senetleri |
| Campbell & CO Investment Adviser LLC | $1.106.563 | 230.534 | 0,22% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1.080.475 | 225.099 | 0,22% | Hisse senetleri |
| Squarepoint Ops LLC | $999.096 | 208.145 | 0,20% | Hisse senetleri |
| MARTINGALE ASSET MANAGEMENT L P | $926.880 | 193.100 | 0,19% | Hisse senetleri |
| RHUMBLINE ADVISERS | $909.224 | 189.423 | 0,18% | Hisse senetleri |
| STRS OHIO | $810.720 | 168.900 | 0,16% | Hisse senetleri |
| Bank of New York Mellon Corp | $801.067 | 166.889 | 0,16% | Hisse senetleri |
| Caption Management, LLC | $720.000 | 150.000 | 0,15% | Alım opsiyonu |
| Caption Management, LLC | $720.000 | 150.000 | 0,15% | Satım opsiyonu |
| Hudson Bay Capital Management LP | $720.000 | 150.000 | 0,15% | Hisse senetleri |
| Wealth Management Associates, Inc. | $710.376 | 147.995 | 0,14% | Hisse senetleri |
| WELLINGTON MANAGEMENT GROUP LLP | $701.467 | 146.139 | 0,14% | Hisse senetleri |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $643.433 | 142.985 | 0,13% | Hisse senetleri |
| ALLIANCEBERNSTEIN L.P. | $631.080 | 140.240 | 0,13% | Hisse senetleri |
| Connor, Clark & Lunn Investment Management Ltd. | $619.685 | 129.101 | 0,12% | Hisse senetleri |
| BlackRock, Inc. | $567.398 | 118.208 | 0,11% | Hisse senetleri |
| Front Row Advisors LLC | $516.035 | 110.500 | 0,10% | Hisse senetleri |
| BARCLAYS PLC | $499.320 | 104.025 | 0,10% | Hisse senetleri |
| Rafferty Asset Management, LLC | $490.416 | 102.170 | 0,10% | Hisse senetleri |
| MetLife Investment Management, LLC | $452.885 | 94.351 | 0,09% | Hisse senetleri |
| VANGUARD ASSET MANAGEMENT, Ltd | $429.994 | 89.582 | 0,09% | Hisse senetleri |
| TWO SIGMA INVESTMENTS, LP | $407.933 | 84.986 | 0,08% | Hisse senetleri |
| JBF Capital, Inc. | $385.349 | 80.281 | 0,08% | Hisse senetleri |
| Integrated Quantitative Investments LLC | $383.698 | 79.937 | 0,08% | Hisse senetleri |
| Virtus Investment Advisers, LLC | $368.674 | 76.807 | 0,07% | Hisse senetleri |
| XTX Topco Ltd | $365.808 | 76.210 | 0,07% | Hisse senetleri |
| AMERICAN CENTURY COMPANIES INC | $317.832 | 66.215 | 0,06% | Hisse senetleri |
| Invesco Ltd. | $305.616 | 63.670 | 0,06% | Hisse senetleri |
| Rockefeller Capital Management L.P. | $302.400 | 63.000 | 0,06% | Hisse senetleri |
| Creative Planning | $298.133 | 62.111 | 0,06% | Hisse senetleri |
| JANUS HENDERSON GROUP PLC | $273.746 | 60.900 | 0,06% | Hisse senetleri |
| Quantinno Capital Management LP | $273.413 | 56.961 | 0,06% | Hisse senetleri |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $265.118 | 55.233 | 0,05% | Hisse senetleri |
| Vanguard Global Advisers, LLC | $264.730 | 55.152 | 0,05% | Hisse senetleri |
| Mitsubishi UFJ Asset Management Co., Ltd. | $255.936 | 53.320 | 0,05% | Hisse senetleri |
| Jump Financial, LLC | $255.178 | 53.162 | 0,05% | Hisse senetleri |
| PROFUND ADVISORS LLC | $254.482 | 53.017 | 0,05% | Hisse senetleri |
| WOLVERINE TRADING, LLC | $248.868 | 55.800 | 0,05% | Alım opsiyonu |
| Police & Firemen's Retirement System of New Jersey | $248.203 | 51.709 | 0,05% | Hisse senetleri |
| Exome Asset Management LLC | $240.797 | 50.166 | 0,05% | Hisse senetleri |
| Magnetar Financial LLC | $225.922 | 47.067 | 0,05% | Hisse senetleri |
| State of New Jersey Common Pension Fund D | $221.602 | 46.167 | 0,04% | Hisse senetleri |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $212.664 | 44.305 | 0,04% | Hisse senetleri |
| ALLSTATE CORP | $212.285 | 44.226 | 0,04% | Hisse senetleri |
| Quadrature Capital Ltd | $201.619 | 42.004 | 0,04% | Hisse senetleri |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $189.475 | 39.474 | 0,04% | Hisse senetleri |
| ARIZONA STATE RETIREMENT SYSTEM | $189.110 | 39.398 | 0,04% | Hisse senetleri |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $175.680 | 36.600 | 0,04% | Alım opsiyonu |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $171.936 | 35.820 | 0,03% | Hisse senetleri |
| NEW YORK STATE COMMON RETIREMENT FUND | $169.286 | 35.268 | 0,03% | Hisse senetleri |
| INTECH INVESTMENT MANAGEMENT LLC | $167.208 | 34.835 | 0,03% | Hisse senetleri |
| Mitsubishi UFJ Trust & Banking Corp | $152.102 | 31.688 | 0,03% | Hisse senetleri |
| VOYA INVESTMENT MANAGEMENT LLC | $151.070 | 31.473 | 0,03% | Hisse senetleri |
| China Universal Asset Management Co., Ltd. | $150.902 | 31.438 | 0,03% | Hisse senetleri |
| Vanguard Investments Australia, Ltd. | $150.182 | 31.288 | 0,03% | Hisse senetleri |
| KLP KAPITALFORVALTNING AS | $148.320 | 30.900 | 0,03% | Hisse senetleri |
| Premier Path Wealth Partners, LLC | $144.000 | 30.000 | 0,03% | Hisse senetleri |
| BNP PARIBAS FINANCIAL MARKETS | $139.675 | 29.099 | 0,03% | Hisse senetleri |
| SHERBROOKE PARK ADVISERS LLC | $134.627 | 27.989 | 0,03% | Hisse senetleri |
| EntryPoint Capital, LLC | $134.112 | 27.940 | 0,03% | Hisse senetleri |
Şirket yöneticileri 25 içeriden öğrenenler · 13 yöneticiler · 11 yönetim kurulu üyeleri
| İçeriden Öğrenen | Rol | Son işlem | Sahip olunan hisse senetleri | Alımlar 12ay | Satışlar 12ay | Net 12ay |
|---|---|---|---|---|---|---|
| William H. Collier | President and CEO | 24 Haziran 2019 A | — | 0 | 0 | $0 |
| Mark J. Murray | President and CEO | 01 Mart 2019 A | 341.396 | 0 | 0 | $0 |
| David C Hastings | Chief Financial Officer | 01 Mart 2019 A | — | 0 | 0 | $0 |
| Bruce Cousins | EVP & Chief Financial Officer | 24 Mart 2017 A | — | 0 | 0 | $0 |
| Gaston Picchio | Chief Development Officer | 01 Mart 2019 A | — | 0 | 0 | $0 |
| Elizabeth Howard | Executive VP & General Counsel | 01 Mart 2019 A | — | 0 | 0 | $0 |
| Michael J. Mcelhaugh | Chief Business Officer | 01 Mart 2019 A | — | 0 | 0 | $0 |
| Michael J. Sofia | Chief Scientific Officer | 01 Mart 2019 A | 1.503.403 | 0 | 0 | $0 |
| Koert Vandenenden | Chief Accounting Officer | 11 Aralık 2018 A | — | 0 | 0 | $0 |
| William T. Symonds | Chief Development Officer | 16 Nisan 2018 A | — | 0 | 0 | $0 |
| Peter Lutwyche | Chief Technology Officer | 24 Mart 2017 A | — | 0 | 0 | $0 |
| Michael J. Abrams | Managing Director | 16 Ağustos 2016 M | 42.097 | 0 | 0 | $0 |
| Mark Kowalski | Sr VP & Chief Medical Officer | 15 Mart 2016 A | — | 0 | 0 | $0 |
| Roger Sawhney | Yönetim kurulu üyesi | 08 Haziran 2026 A | — | 0 | 0 | $0 |
| Robert A Beardsley | Yönetim kurulu üyesi | 08 Haziran 2026 A | — | 0 | 0 | $0 |
| Frank Torti | Yönetim kurulu üyesi | 26 Kasım 2018 A | — | 0 | 0 | $0 |
| Vivek Ramaswamy | Yönetim kurulu üyesi | 19 Haziran 2018 A | — | 0 | 0 | $0 |
| Keith S Manchester | Yönetim kurulu üyesi | 19 Haziran 2018 A | — | 0 | 0 | $0 |
| Daniel D Burgess | Yönetim kurulu üyesi | 19 Haziran 2018 A | — | 0 | 0 | $0 |
| Herbert J Conrad | Yönetim kurulu üyesi | 19 Haziran 2018 A | — | 0 | 0 | $0 |
| Richard C Henriques JR | Yönetim kurulu üyesi | 19 Haziran 2018 A | 1.000 | 0 | 0 | $0 |
| Frank Karbe | Yönetim kurulu üyesi | 21 Haziran 2017 A | — | 0 | 0 | $0 |
| Roivant Sciences Ltd. | 10% sahip | 18 Ekim 2021 C | 38.847.462 | 0 | 0 | $0 |
| Andrew Lo | 10% sahip | 12 Ocak 2018 P | — | 0 | 0 | $0 |
| Patrick Machado | 10% sahip | 12 Ocak 2018 P | — | 0 | 0 | $0 |
SEC Form 3/4/5 başvurularından yöneticiler; net = yalnızca açık piyasa Alış/Satış
Aktivistler ve %5+ sahipler 8 pozisyon
SEC Çizelge 13D dosyalayan yatırımcılar — ihraççı üzerinde nüfuz etme niyetiyle %5'in üzerinde faydalı sahiplik (aktivist hisseler, yönetim kurulu kampanyaları, M&A). Her satır, o başvuru sahibinin pozisyonunun bilinen en son durumunu gösterir.
| Başvuru sahibi | Dosyalandı | Hisse | Durum | Amaç | Başvuru |
|---|---|---|---|---|---|
| Whitefort Capital Master Fund, LP, Whitefort Capital GP, LLC, Whitefort Capital Management, LP, Whitefort Capital Management GP, LLC, David Salanic, Joseph Kaplan ×5 başvurular | 28 Nisan 2026 | 8,00% | Değişiklik | — | SEC |
| Roivant Sciences Ltd. ×14 başvurular | 25 Şubat 2025 | 20,50% | Değişiklik | — | SEC |
| Patrick Machado ×4 başvurular | 17 Temmuz 2019 | — | İlk başvuru | — | SEC |
| Dr. Andrew Lo ×5 başvurular | 17 Temmuz 2019 | — | İlk başvuru | — | SEC |
| SVF Investments (UK) Limited, SVF Holdings (UK) LLP, SoftBank Vision Fund L.P., SVF GP (Jersey) Limited ×4 başvurular | 12 Temmuz 2019 | — | İlk başvuru | — | SEC |
| QVT Financial LP, QVT Financial GP LLC, QVT Family Office Fund LP, QVT Associates GP LLC ×6 başvurular | 12 Temmuz 2019 | — | İlk başvuru | — | SEC |
| Dexxon Holdings Ltd., Dexcel Pharma Technologies Ltd., Dan Oren ×6 başvurular | 12 Temmuz 2019 | — | İlk başvuru | — | SEC |
| Viking Global Investors LP, Viking Global Performance LLC, Viking Global Equities LP, Viking Global Equities II LP, VGE III Portfolio Ltd., Viking Global Equities Master Ltd., Viking Long Fund GP LLC, Viking Long Fund Master Ltd., Viking Global Opportunities GP LLC, Viking Global Opportunities Portfolio GP LLC, Viking Global Opportunities Illiquid Investments Sub-Master LP, O. Andreas Halvorsen, David C. Ott, Rose S. Shabet ×7 başvurular | 12 Temmuz 2019 | — | İlk başvuru | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF sahipliği 34 ETF'ler tarafından tutuluyor
Ağırlık yalnızca doğrudan öz sermaye varlıklarını (N-PORT) yansıtır; kaldıraçlı veya türev tabanlı fonlar gösterilmeyen ek swap pozisyonlarına sahip olabilir.
| Fon | Ağırlık | Birimler | Tarih itibarıyla | Kaynak |
|---|---|---|---|---|
| BBC · ETFis Series Trust I | 0,66% | 58.600 NS | 30 Nisan 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0,11% | 132.235 NS | 30 Nisan 2026 | N-PORT |
| BIB · ProShares Trust | 0,04% | 7.110 NS | 31 Mayıs 2026 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0,03% | 64.366 NS | 31 Mayıs 2026 | N-PORT |
| RSSL · Global X Funds | 0,02% | 65.520 NS | 30 Nisan 2026 | N-PORT |
| ITWO · ProShares Trust | 0,02% | 7.126 NS | 31 Mayıs 2026 | N-PORT |
| SCHA · SCHWAB STRATEGIC TRUST | 0,01% | 734.401 NS | 31 Mayıs 2026 | N-PORT |
| UWM · ProShares Trust | 0,01% | 5.554 NS | 31 Mayıs 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0,01% | 64.437 NS | 30 Nisan 2026 | N-PORT |
| URTY · ProShares Trust | 0,01% | 5.639 NS | 31 Mayıs 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,00% | 5.309 NS | 31 Mayıs 2026 | N-PORT |
| HDG · ProShares Trust | 0,00% | 141 NS | 31 Mayıs 2026 | N-PORT |
| SCHB · SCHWAB STRATEGIC TRUST | 0,00% | 86.163 NS | 31 Mayıs 2026 | N-PORT |
| AVSC · AMERICAN CENTURY ETF TRUST | 0,00% | 4.760 NS | 31 Mayıs 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | — | — | 15 Temmuz 2026 | Günlük |
| VTI · VANGUARD INDEX FUNDS | — | — | 15 Temmuz 2026 | Günlük |
| VTWO · VANGUARD SCOTTSDALE FUNDS | — | — | 15 Temmuz 2026 | Günlük |
| VTWG · VANGUARD SCOTTSDALE FUNDS | — | — | 15 Temmuz 2026 | Günlük |
| VTHR · VANGUARD SCOTTSDALE FUNDS | — | — | 15 Temmuz 2026 | Günlük |
| ITOT · iShares Trust | — | — | 22 Temmuz 2026 | Günlük |
| IWV · iShares Trust | — | — | 18 Ağustos 2026 | Günlük |
| IWO · iShares Trust | — | — | 18 Ağustos 2026 | Günlük |
| IWM · iShares Trust | — | — | 18 Ağustos 2026 | Günlük |
| IBB · iShares Trust | — | — | 18 Ağustos 2026 | Günlük |
| IWC · iShares Trust | — | — | 18 Ağustos 2026 | Günlük |
| PRFZ · Invesco Exchange-Traded Fund Trust | — | — | 13 Temmuz 2026 | Günlük |
| VHT · VANGUARD WORLD FUND | — | — | 20 Temmuz 2026 | Günlük |
| ISCB · iShares Trust | — | — | 20 Temmuz 2026 | Günlük |
| ISCG · iShares Trust | — | — | 21 Temmuz 2026 | Günlük |
| ISCV · iShares Trust | — | — | 20 Temmuz 2026 | Günlük |
| SMMV · iShares Trust | — | — | 18 Ağustos 2026 | Günlük |
| WSML · iShares Trust | — | — | 20 Temmuz 2026 | Günlük |
| IBBQ · Invesco Exchange-Traded Fund Trust … | — | — | 20 Temmuz 2026 | Günlük |
| QQQS · Invesco Exchange-Traded Fund Trust … | — | — | 20 Temmuz 2026 | Günlük |